Tata Chemicals Q3 Review - Recovery In Soda Ash Demand On The Way: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Tata Chemicals Ltd.’s consolidated Ebitda was ahead of our estimate, even after adjusting for one-time insurance gain.
Ebitda performance was above our estimates across geographies (barring Europe). Performance in North America was hit by a fall in exports and pressure on realizations.
Its India operations clocked higher volumes, but margin was impacted due to pressure on realization.
Factoring in Q3 performance, we have raised our FY21E earnings estimate by 20% and by 12% each for FY22E/FY23E on the back of an expansion at the Mithapur plant.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.